Trade Sage Therapeutics, Inc. - SAGE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 13.14 |
| Open | 13.1 |
| 1-Year Change | -73.03% |
| Day's Range | 12.82 - 13.22 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 2, 2024 | 13.05 | -0.18 | -1.36% | 13.23 | 13.31 | 12.75 |
| May 1, 2024 | 13.14 | -0.90 | -6.41% | 14.04 | 14.41 | 13.07 |
| Apr 30, 2024 | 13.82 | -0.01 | -0.07% | 13.83 | 14.41 | 13.74 |
| Apr 29, 2024 | 14.13 | 0.34 | 2.47% | 13.79 | 14.66 | 13.78 |
| Apr 26, 2024 | 13.62 | -0.16 | -1.16% | 13.78 | 13.85 | 13.24 |
| Apr 25, 2024 | 13.54 | -0.13 | -0.95% | 13.67 | 14.87 | 13.44 |
| Apr 24, 2024 | 13.96 | 0.49 | 3.64% | 13.47 | 14.46 | 13.47 |
| Apr 23, 2024 | 12.89 | 0.20 | 1.58% | 12.69 | 13.30 | 12.69 |
| Apr 22, 2024 | 12.84 | -0.46 | -3.46% | 13.30 | 13.30 | 12.79 |
| Apr 19, 2024 | 13.28 | 0.28 | 2.15% | 13.00 | 13.56 | 12.88 |
| Apr 18, 2024 | 12.97 | 0.83 | 6.84% | 12.14 | 13.43 | 12.03 |
| Apr 17, 2024 | 12.47 | -0.40 | -3.11% | 12.87 | 13.26 | 10.85 |
| Apr 16, 2024 | 15.51 | 0.46 | 3.06% | 15.05 | 15.69 | 14.93 |
| Apr 15, 2024 | 15.20 | -0.16 | -1.04% | 15.36 | 15.52 | 14.98 |
| Apr 12, 2024 | 15.39 | -0.70 | -4.35% | 16.09 | 16.20 | 15.23 |
| Apr 11, 2024 | 16.51 | 0.08 | 0.49% | 16.43 | 16.65 | 16.15 |
| Apr 10, 2024 | 16.37 | 0.25 | 1.55% | 16.12 | 16.48 | 15.75 |
| Apr 9, 2024 | 16.47 | 0.04 | 0.24% | 16.43 | 16.98 | 16.18 |
| Apr 8, 2024 | 16.55 | 0.35 | 2.16% | 16.20 | 16.70 | 16.13 |
| Apr 5, 2024 | 16.31 | -0.03 | -0.18% | 16.34 | 16.71 | 15.80 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sage Therapeutic Company profile
About SAGE Therapeutics Inc
SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).
Equity composition
Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.
| Industry: | Bio Therapeutic Drugs |
215 1st St
CAMBRIDGE
MASSACHUSETTS 02142
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com